Colchicine for Secondary Prevention After Ischemic Stroke (CHANCE-3 EX)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 7500 participants.

Also called NCT07035405

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 7,500 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07035405
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07035405. Randomized; quadruple masking; primary purpose prevention. Start 2025-07-04 (anticipated); primary completion 2028-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Colchicine for Secondary Prevention After Ischemic Stroke (CHANCE-3 EX)
Condition
Stroke
Intervention (Drug)
Colchicine 0.5 mg
Intervention (Drug)
Placebo colchicine
Lead sponsor
Beijing Tiantan Hospital (class: other)
Collaborator
Shenzhen Medical Academy of Research and Translation (class: not stated)

Record details

Record id
cardio:ct-nct07035405
Content hash
4833a18a80b2ddbac480fa167c0be2172651c3cc746d85af28eda03e7e117e7f